Biodesix, Inc. (NASDAQ:BDSX) Insider Sells $15,408.16 in Stock

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of Biodesix stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $15,408.16. Following the completion of the sale, the insider now owns 156,008 shares of the company’s stock, valued at approximately $143,527.36. The trade was a 9.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Biodesix Stock Performance

Shares of BDSX stock opened at $0.96 on Friday. The firm has a 50 day moving average of $1.24 and a 200-day moving average of $1.49. The company has a market cap of $140.09 million, a price-to-earnings ratio of -2.47 and a beta of 1.06. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 52 week low of $0.86 and a 52 week high of $2.04.

Institutional Investors Weigh In On Biodesix

A number of large investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. raised its holdings in shares of Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after purchasing an additional 310,000 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix in the 3rd quarter valued at about $262,000. Barclays PLC increased its position in Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares in the last quarter. Geode Capital Management LLC raised its stake in Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after buying an additional 270,724 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Biodesix during the 3rd quarter worth approximately $10,849,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.